OTLC — Oncotelic Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Oxigene to advance fosbretabulin in two late-stage clinical trials
Brief: Oxigene Qtrly loss per share $0.13
Brief: Oxigene appoints Matthew M. Loar as CFO
Brief: Oxigene CFO Barbara Riching resigns
Brief: OxiGENE gets FDA nod for ovarian cancer drug study design
Brief: Oxigene files for mixed shelf of up to $75 mln
Brief: Oxigene appoints Bill Schwieterman as President and Chief Executive Officer
Brief: Oxigene Qtrly loss per share $0.13
Brief: Oxigene announces $10 mln at-the-market registered direct offering
Brief: Oxigene granted European patent for drug used in acute myeloid leukemia and other myeloid malignancies
Brief: Oxigene announces issuance of European patent for OXi4503 in Acute Myeloid Leukemia and other myeloid malignancies
Brief: Oxigene reports Q3 loss per share $0.17
Brief: Oxigene announces presentation of phase 2 data confirming that addition of Fosbretabulin to Bevacizumab significantly increases progression-free survival in recurrent Ovarian cancer
US STOCKS-Wall St declines on China, Ukraine concerns
Oxigene Inc says drug meets main goal of ovarian cancer trial
Market Pulse: Apple, McDonald's, Crosstex, Tellabs, Voxeljet
Market Pulse: Scholastic, MBIA, Cirrus Logic, Tilly, Skechers
Market Pulse: Scholastic, MBIA, Cirrus Logic, Tilly, Skechers
Market Pulse: Scholastic, MBIA, Cirrus Logic, Tilly, Skechers